Skip to main content
Clinical Trials/IRCT201205131556N42
IRCT201205131556N42
Completed
Phase 2

The effect of raloxifene in postmenopausal women with chronic schizophrenia: a randomized double blind and placebo controlled trial

Tehran University of Medical Sciences0 sites46 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
46

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
Female

Inclusion Criteria

  • Inclusion Criteria: Postmenopausal women, Diagnosis of Schizophrenia based on DSM IV , chronic Schizophrenia( duration of the disorder\>2 years), Minimum Score of 20 on Negative subscale

Exclusion Criteria

  • Substance dependence( except for nicotine and cafeine), IQ \<70, any other mental disorder on axis I, Any serious medical or neurological problem , receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month, receiving ECT during the last 14 days,hepatic and renal disease , Endocrine abnormality, history of thrombosis and emboli, history of abnormal uterine bleeding, uterine or breast cancer, history of CVA, Hormone replacement therapy

Investigators

Similar Trials